In the BCR-ABL positive CML patient primary cells, CHMFL-074 exhibited half effective inhibitory concentrations between 0.3–1 μM which followed similar trend as Imatinib (Figure 3B). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.